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fi rst-person informed consent are valid and important, 
justice requires the creation of guidance and procedures 
that will allow these individuals to benefi t from scientifi c 
advances while ensuring that their interests are protected.
To address this signifi cant inconsistency in the over-
sight and conduct of research, the Task Force drafted a 
set of legal and ethical guidance regarding the conduct 
of research in New York State involving adults who lack 
consent capacity. This article addresses the development 
and key content of the guidance, which may serve as a 
model for research in other states and at the federal level. 
An underlying goal of the work is to ensure that research 
protocols are available to all individuals, including this 
population, so that they may also experience the ben-
efi ts of research and share its risks and burdens as their 
non-cognitively impaired peers, while also ensuring the 
appropriate level of protections. Thus, the report provides 
guidance and best practices that will assist institutions, 
researchers, IRBs, and surrogate decision-makers in the 
ethical conduct and responsibilities of research involving 
the cognitively impaired. Without such guidance, either 
research will occur without appropriate protections and 
safeguards, or important research may not occur.
Methods
At the request of various stakeholders, the Task Force 
analyzed the legal and ethical implications of research 
involving adults lacking consent capacity. The Task Force 
began this endeavor in December 2007 by disseminating 
a survey to approximately 300 New York IRB chairs and 
members that requested information about their institu-
tions’ practices, if any, for conducting research involving 
the cognitively impaired, and their views on the regu-
latory landscape. More than 100 responses provided a 
detailed and useful qualitative account of research prac-
tices in New York, and indicated a need for guidelines to 
ensure consistently ethical research practices. 
Since 2007, the Task Force has devoted itself to exam-
ining the issues associated with research involving cog-
nitively impaired adults. It reviewed medical and policy 
literature on human subjects research, informed consent, 
surrogate consent, capacity assessment, risk-benefi t 
analysis, research protections, adverse events, and related 
topics. It conducted extensive legal research of federal and 
state regulatory standards, including New York’s, and 
case studies pertaining to human subjects research involv-
ing the cognitively impaired. It reached out and relied on 
American history has been rife with human subjects 
research (HSR) scandals—particularly those that involve 
“vulnerable” populations—including several in New 
York State, such as those that occurred at the Willow-
brook State School and the Jewish Chronic Disease Hos-
pital.1 In response, state and federal laws and regulations 
were enacted to ensure voluntary informed consent for 
participants and institutional review board (IRB) over-
sight of HSR. However, these laws and regulations do not 
provide any special oversight mechanisms or protections 
to ensure the ethical and safe inclusion of cognitively 
impaired adults in research.
Although research involving adults lacking consent 
capacity is permitted in New York State, until recently it 
was limited because of uncertainty about who could pro-
vide surrogate consent to participation. In 2010, the Fami-
ly Health Care Decisions Act changed the legal landscape 
by permitting surrogate consent to health care and poten-
tially opened up the fi eld of research requiring surrogate 
consent. However, there remain few—if any—rules and 
little guidance at both the federal and state level to ensure 
consistently ethical conduct of research involving adults 
lacking consent capacity. While some institutions and 
investigators are conducting researching with this popu-
lation without oversight or guidance, others are taking an 
extremely conservative approach and are excluding these 
individuals from research, citing concerns about vulner-
ability and exploitation. Without safeguards that are both 
adequate and robust but not overly burdensome, this 
will remain a challenge to the conduct of ethical research. 
Thus, IRBs, investigators, and research institutions have 
appealed to the New York State Task Force on Life and 
the Law (the Task Force)2 for guidance on how to conduct 
research involving this vulnerable population.
Human subjects research plays an essential role 
in advancing biomedical and behavioral science and 
strengthening our ability to prevent and treat human dis-
eases and medical conditions. The optimal condition for 
research involving human subjects is for the participant 
to provide fi rst-person informed consent. To learn about 
and seek cures for the broad range of diseases that impair 
cognition, however, research requires the participation 
of individuals who cannot themselves provide informed 
consent. Laws that exclude individuals who lack con-
sent capacity actually disadvantage this population by 
preventing scientifi c advances for conditions that cause 
decisional incapacity. Although concerns about how to 
conduct research involving individuals unable to give 
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choosing the least burdened population. If researchers 
propose to utilize nursing home residents or institutional-
ized patients, they should demonstrate why that venue is 
necessary,8 because research involving these groups may 
be seen as increasing the risks and potential harms for an 
already burdened population.9 
Where possible, particularly for high risk or no-
direct-benefi t research, IRBs should require research 
protocols to include evidence of safety and effi cacy data 
from studies conducted in a non-impaired group prior to 
inclusion of cognitively impaired individuals. However, 
in certain circumstances, the potential benefi t is unique to 
the cognitively impaired population, or the characteristics 
of the non-impaired participants may differ so greatly 
from the impaired population that such evidence may not 
be available.
B. Benefi ts and Risks
The Task Force recommends that, in reviewing pro-
posed research protocols, IRBs consider whether same 
or similar benefi ts are available outside the context of 
research, the intent of the researcher and purpose of the 
study, the likelihood that all participants will receive the 
benefi t, and the extent or amount of the potential direct 
benefi t. 
One of the core functions of an IRB is to review and 
approve studies that present a reasonable balance of 
potential benefi ts to risks. Research protocols can be clas-
sifi ed as either prospect-of-direct-benefi t or no-direct-benefi t 
studies, based on the likelihood that the research will 
result in direct benefi ts that improve the health or well-
being of a participant by procedures or interventions that 
are outside of standard health care treatment. Prospect-
of-direct-benefi t research has a reasonable probability of 
providing the proposed benefi t. No-direct-benefi t studies 
have a negligible or nonexistent probability of offering a 
benefi t to participants. 
One of the most complex ethical issues in conducting 
research involving these individuals is the degree of risk 
to which researchers may ethically expose this popula-
tion. While upper limits on the level of acceptable risk 
may be necessary for some HSR studies, bright-line cut-
offs are only appropriate in limited circumstances. The 
Task Force recommends that research should only be ap-
proved for individuals who have fi rst explored all avail-
able treatment and research options and failed to receive 
any therapeutic benefi t, and for those without any other 
known treatment or research options available. 
In 1977, the National Commission issued a report 
on research involving children, suggesting a tripartite 
scheme for classifying research risks.10 These three clas-
sifi cations are: (1) minimal risk; (2) minor increase over 
minimal risk; and (3) more than a minor increase over 
minimal risk. This scheme was incorporated into the 
federal regulations for research with children11 and has 
testimony from several experts from research institutions, 
governmental entities, and patient advocacy organi-
zations. The Task Force analyzed previously released 
reports, recommendations, and draft regulations on hu-
man subjects research by the Department of Health and 
the public comments to these efforts,3 and stakeholders 
and other interested parties provided additional perspec-
tives and input on this project. It also took into account 
the controversial advisory opinion in the case T.D. v. N.Y. 
State Offi ce of Mental Health,4 in which the court addressed 
the need for special protections where research includes 
individuals who lack consent capacity when surrogate 
consent is used.
In developing these guidelines, the Task Force con-
sidered and declined to recommend legislation govern-
ing research involving individuals who lack consent 
capacity. It concluded that because existing law permits 
research involving this population,5 no statutory change 
is needed. The Task Force therefore identifi ed approaches 
that comply with current federal and state law, including 
the Common Rule and New York Public Health Law 24-
A,6 to ensure ethical practices in research involving this 
vulnerable population.
Recommendations
In order to promote a consistently ethical approach 
by institutions to the protection of this vulnerable popu-
lation in New York State, the Task Force made a number 
of important and—in some cases—unique recommenda-
tions regarding including individuals who lack consent 
capacity in human subjects research.7 This guidance is 
necessary in order to ensure that this population is able 
to participate in research (as the law anticipates) with 
adequate and appropriate safeguards in place.
A. Participant Selection
The Task Force recommends that researchers and 
IRBs must ensure that there is justifi cation for involving 
participants who lack consent capacity in research proto-
cols, and in general, that the least burdened populations 
should be used as research participants wherever pos-
sible. Availability, compromised position, or ease of re-
cruitment are insuffi cient reasons to justify the inclusion 
of a specifi c vulnerable group in research. The inclusion 
of such individuals may be appropriate in research that 
offers potential benefi ts to participants when standard 
clinical approaches are ineffective, unproven, or unsatis-
factory, or when research is reviewing a new, improved 
standard of care that may be more effective for conditions 
that uniquely affect that specifi c population. Further-
more, IRBs should pay particular attention to the ratio-
nale behind enrolling vulnerable patients for research 
protocols that do not explicitly study medical conditions 
that impair consent capacity.
In addition, the Task Force recommends that the in-
stitutional setting for research must be scrutinized when 
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should be unique to each study, and should be calibrated 
according to the risk level and the likelihood and signifi -
cance of any direct benefi t.
The Task Force recommends the following approach 
to oversee risk-benefi t ratios for research involving indi-
viduals lacking consent capacity:
For research with minimal risk and a prospect of direct 
benefi t to the participant, IRBs may approve such studies 
if the risks are reasonable in relation to the prospective 
benefi ts. 
For research with minimal risk and no prospect of direct 
benefi t to the participant, IRBs may approve such stud-
ies if the research is important to advance the scientifi c 
knowledge of a medical condition that affects the research 
population, and if the risks are reasonable in relation to 
such importance. Ethical issues related to research with 
minimal risk, with or without a prospect of direct ben-
efi t, are often manageable. IRBs, researchers, surrogate 
decision-makers, and potential participants should expect 
to resolve them without severely impeding research 
or unreasonably risking the participants’ welfare, par-
ticularly when the benefi cial prospect is more certain, 
or the benefi t is expected to be more frequent or more 
signifi cant.
For research with a minor increase over minimal risk 
and a prospect of direct benefi t to the participant, IRBs may 
approve such studies only if the risks are reasonable in re-
lation to the prospective benefi ts, if the potential benefi ts 
are similar to those available in the standard clinical or 
treatment setting, and if the risk-benefi t ratio is favorable 
to participants. Such ratios are more favorable when the 
benefi cial prospect is more certain or the benefi t is ex-
pected to be more frequent or more signifi cant. IRBs may 
recommend the use of ICMs, MRCs, or other additional 
safeguards.
For research with a minor increase over minimal risk 
and no prospect of direct benefi t to the participant, IRBs may 
approve such studies only if the research is vitally impor-
tant to further the understanding of the etiology, preven-
tion, diagnosis, pathophysiology, or alleviation or treat-
ment of a condition or disorder that affects the research 
population, and if the risks are reasonable in relation to 
the research’s “vital importance.”16 Furthermore, IRBs 
may approve such studies only if they require mandatory 
rigorous procedures and oversight for enrollment and 
monitoring of participants through the use of safeguards, 
including an ICM and an MRC.
For research with a more than a minor increase over 
minimal risk and a prospect of direct benefi t to the partici-
pant, IRBs may approve such studies only if the risks 
are reasonable in relation to the prospective benefi ts, if 
the potential benefi ts are similar to those available in the 
standard clinical or treatment setting, and if the risk-
benefi t ratio is favorable to participants. Such ratios are 
been used in numerous expert commission reports and 
state regulations delineating research risk in all human 
subjects research.12 Although the tripartite risk scheme 
presents diffi culties in application, it remains the most 
recognized and most used method to classify risks levels. 
The Task Force concluded that these three major risk 
levels are appropriate for IRBs and researchers to use for 
research involving individuals who lack consent capacity. 
The Task Force recommends that for all human sub-
jects research, the risk level should be minimized wher-
ever possible to achieve the research objective. Although 
risk may never be eliminated completely in some studies, 
the Task Force recommends that procedures should be 
in place to assure an appropriate level of care for partici-
pants, including personalized attention to ensure safety 
and the use of required medical and therapeutic proce-
dures where appropriate. 
When research involves vulnerable individuals, the 
Task Force recommends that it is appropriate for IRBs 
to establish a lower ceiling for allowable risk or require 
a more favorable risk-benefi t ratio for a protocol to be 
approved than they would for similar research involving 
non-vulnerable participants. However, for research that 
may offer a prospect of direct benefi t, an IRB may allow a 
higher ceiling for allowable risk and allow a less favor-
able risk-benefi t ratio for research. 
For research that is categorized as offering no pros-
pect of direct benefi t, it may nevertheless be unclear 
whether the study has more than a negligible prospect of 
direct benefi t or, if more than negligible, how much more; 
clarity (or its absence) often depends on the current state 
of available scientifi c knowledge. In such cases, where 
research offers no clear prospect of direct benefi t, IRBs 
should determine whether the research is of “vital impor-
tance.” For research to be considered of vital importance, 
there must be clear and signifi cant scientifi c evidence 
that the use of such a procedure or intervention presents 
a reasonable opportunity to further the understanding 
of the etiology, prevention, diagnosis, pathophysiology, 
or alleviation or treatment of a condition or disorder.13 
The IRB should carefully review the hypotheses of the 
study and antecedent evidence, such as data from animal 
studies, analogous research,14 or toxicity trial results, to 
evaluate whether the research is vitally important to the 
research population and will contribute knowledge about 
the disorder or condition. Furthermore, the IRB should 
also examine the researchers’ therapeutic intent15 and the 
purpose of the research study to determine whether the 
research is of vital importance and should be approved.
The Task Force recommends that it is acceptable for 
IRBs to require additional safeguards (such as requiring 
or recommending informed consent monitors (ICMs) and 
medically responsible clinicians (MRCs)) to ensure the 
safety and well-being of vulnerable participants. Both the 
degree of scrutiny by an IRB and the determination of 
the number and type of additional protections required 
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is of vital importance to the understanding of the etiol-
ogy, prevention, diagnosis, pathophysiology, or allevia-
tion or treatment of a condition or disorder that affects 
the research population, and if the risks are reasonable 
in relation to the research’s vital importance. Such risks 
are less likely to be reasonable if they are substantially, 
rather than marginally, more than a minor increase over 
minimal risk. In addition, as noted above, although this 
type of research protocol must be labeled as offering no 
prospect of direct benefi t, for some research participants, 
a remote possibility exists that they (or others similarly 
situated) may benefi t from the research or from the 
knowledge gained.17 In such cases, the IRB must con-
sider whether this remote possibility of benefi t exists for 
potential participants, and weigh it against the potential 
risks of the protocol. Furthermore, the IRB should ensure 
that the study requires rigorous procedures and oversight 
for enrollment and monitoring of participants through the 
use of safeguards, including an ICM and MRC. 
If the IRB concludes that the research is of vital 
importance to either current research participants and/
or those similarly situated, that the risks are reasonable 
in relation to such vital importance, and appropriate 
safeguards are in place, such as the ICM and MRC ad-
dressed above, the IRB should notify the Department of 
Health. At the discretion of the Department of Health, 
the Department may: (1) reject the study (and thus the 
research could not be approved by the IRB), (2) approve 
the study (whereby the research could be approved by 
the IRB), or (3) convene a special review panel of experts18 
who will examine the study and issue recommendations 
to the IRB on whether the study should be approved. If 
the Department of Health decides that a special review 
panel must examine the protocol, after the special panel 
has made its recommendations, the Department should 
refer the protocol back to the IRB for review and the IRB 
will make the fi nal determination based on the panel’s 
recommendations.
The special review panel should be comprised 
of experts knowledgeable about the conditions(s) or 
population(s) addressed by the research, to ensure that 
the reviewers are well-informed about the research topic 
and can provide meaningful commentary to aid in the 
IRB’s decision-making.19 While the Task Force acknowl-
edges that the use of a special review panel may delay 
approval or the commencement of the study, this pro-
cedural process is important to safeguard participants. 
Furthermore, because only a small proportion of state-
regulated research would fall into this risk-benefi t cat-
egory, the number of protocols that would be referred to 
a special review panel would likely be small. Thus, use of 
these panels would acknowledge the need for innovative 
research using the existing regulatory framework (i.e., 
respecting the IRB purpose and structure) and would also 
ensure that unethical research would not be conducted 
(supporting the IRB’s opinion whether the protocol may 
be approved). 
less favorable when the risk is substantially more than a 
minor increase over minimal risk. Such ratios are more 
favorable when the prospect of direct benefi t is more 
certain, or the benefi t is expected to be more frequent or 
more signifi cant. IRBs should require the use of ICMs and 
MRCs.
For research with more than a minor increase over 
minimal risk and no prospect of direct benefi t to the partici-
pant, IRBs may approve such studies in only two circum-
scribed circumstances: where the potential participants 
have a research advance directive or in special situations 
with notifi cation to the Department of Health and use of 
a special review panel. These two scenarios are addressed 
in the following subsections. 
1. Use of Research Advance Directives (RADs)
The Task Force recommends that IRBs may approve 
studies in this risk-benefi t category if all potential par-
ticipants have, when they still had capacity, executed 
legally binding documents such as Research Advance 
Directives (RADs), which provide an individual’s instruc-
tions for future research participation should s/he lose 
consent capacity, that explicitly state that they are willing 
to participate in this category of research. However, even 
if all participants have signed RADs, IRBs may approve 
such studies only if the research is of vital importance to 
the understanding of the etiology, prevention, diagnosis, 
pathophysiology, or alleviation or treatment of a condi-
tion or disorder that affects the research population and/
or those similarly situated. The IRB must determine that 
such risks are reasonable in relation to the research’s vital 
importance. Such risks are less likely to be reasonable if 
they are substantially, rather than marginally, more than 
a minor increase over minimal risk. Furthermore, IRBs 
may approve such studies only if they require mandatory 
rigorous procedures and oversight for enrollment and 
monitoring of participants through the use of safeguards, 
including an ICM and an MRC. 
2. Notifi cation to the Department of Health and 
Use of a Special Review Panel 
Because so few people have RADs, the Task Force 
concluded that an alternative mechanism for innovative 
research to be approved in very limited circumstances 
may be necessary, and thus there are limited circum-
stances where a research protocol may be considered for 
approval even where potential participants do not have 
RADs. The Task Force therefore recommends a second 
mechanism for IRBs to approve studies with more than 
a minor increase over minimal risk and no prospect of 
direct benefi t. This alternative approval process consists 
of several steps: (1) IRB review, (2) Department of Health 
notifi cation by the IRB and possible referral by the De-
partment to a special review panel, and (3) IRB decision 
to approve or reject the research protocol. 
For a protocol to be considered under this alternative 
process, the IRB must fi rst examine whether the research 
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The Task Force recommends that where a potential 
participant is unable to provide or express assent, re-
searchers must look for signs of dissent—the objection or 
resistance to participate in the study – both at the initia-
tion of the study as well as once the participant is en-
rolled. Researchers should recognize that for this popula-
tion, dissent may not be obvious. Furthermore, if signs of 
dissent are present, the researcher may not enroll or allow 
continued participation of the individual in the study. 
Any participant who enrolls in a research protocol 
has the freedom to withdraw from the study without 
prejudice at any time, and this decision to withdraw 
should be respected. However, participants who have 
impaired consent capacity may be unable to express their 
preference to withdraw from the research. The Task Force 
recommends that researchers develop formal procedures 
to ensure that appropriate withdrawal mechanisms are 
available to the research population, that any withdrawal 
is accomplished with the least risk to the participant, and 
that any withdrawal, including the reason for it, is prop-
erly reported to the IRB.
Consent capacity may be impaired due to medical 
conditions or illnesses, chronic diseases, medication, or 
developmental cognitive impairment.21 Moreover, lack 
of capacity may be temporary or permanent, depending 
on the condition. Consent capacity is best understood 
as occurring along a continuum—it is not simply either 
present or absent. Although an individual may exhibit a 
degree of cognitive impairment, it should not be assumed 
that the person does not retain suffi cient capacity to 
consent or decline to participate in all research studies.22 
Consent capacity has a complicated relationship to clini-
cal diagnosis and is likely to fl uctuate over time and may 
be task-specifi c. Determining whether a participant has 
suffi cient consent capacity depends not only on the indi-
vidual, but on the complexity of the research protocol and 
the risks and benefi ts associated with that protocol. Thus, 
the threshold that distinguishes individuals who meet 
the consent capacity standard varies between research 
protocols. 
Current practices for screening and evaluating con-
sent capacity vary in type23 and quality.24 Selection of the 
best method for assessing consent capacity depends in 
part on the use researchers will make of the outcome. In 
cases where researchers seek to exclude all participants 
who lack consent capacity, briefer screening tools may 
suffi ce. For protocols in which researchers intend to enroll 
impaired individuals who require either remediation or 
other consent enhancement techniques to meet criteria 
for consent capacity, a more detailed evaluation tool may 
be most useful. In addition, proper use of the capacity 
evaluation tool may also be contingent on the inclusion 
or exclusion criteria of the research protocol. The Task 
Force recommends that researchers seeking approval 
of a study involving the cognitively impaired should 
provide the IRB with a description of the procedures and 
Where a protocol has been referred to a special 
review panel by the Department of Health, the panelists 
should be required to provide a written report that will 
be publicly available, which will include a summary of 
the panel’s reasoning, analysis, and recommendation 
to the IRB. The recommendations will advise the IRB to 
either reject or approve the study, and will include any 
modifi cations to the protocol. In the fi nal step of this pro-
cess, the IRB would then review the recommendations 
and decide to approve or reject the study. 
The panelists should also forward their recommen-
dations to the Department of Health for record keeping. 
The Department of Health should keep the individual 
panel members’ recommendations on fi le and make them 
available to the public upon request, which would pro-
vide a historical record of the types of research studies 
considered by these panels. This information may help 
guide researchers as they design future studies, assist 
IRBs with their review and oversight process of this type 
of risk-benefi t research, and promote transparency for the 
general public to maintain confi dence in the oversight 
process of this category of unique research. 
C. Consent and Capacity Assessments
Informed consent is a fundamental tenet of ethically 
and legally acceptable human subjects research because it 
helps protect individuals from involuntary participation 
and exposure to risk. The Task Force recommends that, 
where possible, informed consent should be obtained in 
a dynamic process, as part of a continued dialogue be-
tween the potential participant and the person presenting 
the research protocol. The information should be pre-
sented using methods that are best suited to the capacity 
level of the target population. Asking detailed questions 
and having a discussion about the study with a knowl-
edgeable person will help guide a potential participant in 
making a careful decision about whether research enroll-
ment is appropriate (i.e., fi rst-person decision-making). 
The focus of the informed consent process should be on 
this conversation and comprehension, rather than on the 
technicalities of the consent form. The Task Force recom-
mends that informed consent be obtained, with the use of 
a neutral discloser, before enrollment in a research study, 
but should also be re-obtained when circumstances sig-
nifi cantly change the potential benefi ts or risks or harms, 
or when new scientifi c information becomes available. 
Cognitively impaired adults who do not have the ca-
pacity to provide fi rst-person informed consent may nev-
ertheless retain suffi cient capacity to understand some of 
the more basic concepts involved in a research study and 
provide assent—affi rmative agreement—to participate in 
the proposed research. Therefore, to preserve the auton-
omy of potential participants who are capable of assent, 
the Task Force recommends that researchers must seek 
assent from such participants in addition to informed 
consent from a surrogate.20
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surrogate consent to health care.32 The surrogate hierar-
chy contained in the FHCDA thus opened up the fi eld of 
research requiring surrogate consent in New York State.
While hierarchies are practical for determining who 
may serve as an LAR, not all LARs are ethical equiva-
lents, particularly when considering research enrollment 
decisions. Because LARs listed in a hierarchy often will 
have varying degrees of kinship, intimacy, and under-
standing of the wishes of the impaired individual regard-
ing research participation, it is important to consider the 
relationship between the LAR and the potential partici-
pant with respect to the type of research and risk level 
involved. An LAR who has a close relationship with the 
impaired individual would be the most familiar with 
whether s/he would choose to participate in research and 
under what circumstances. Thus, the Task Force recom-
mends that IRBs and researchers consider limiting the 
classes of LAR(s) who are authorized to provide surrogate 
consent to research. The riskier the research protocol and 
more remote the prospect of benefi t, the closer (by kinship 
or intimacy level) the LAR should be to an individual 
to be imbued with authority to consent to the impaired 
individual’s participation in the study.33 
When determining whether an individual should 
participate in research, an LAR should use instructions 
from an RAD or similar type of advance directive, if such 
instructions exist; or the participant’s prior expressed 
wishes and preferences about research, if known. If there 
are no prior expressed wishes, the LAR should use either 
the best interest standard or substituted judgment. 
Finally, to prevent undue inducement to consent to 
research, LARs may never be the true benefi ciary of any 
fi nancial compensation offered.
E. Notice to Participant and Opportunity for Review
The Task Force emphasized the importance of pro-
cedures for providing notice to the potential research 
participant and, if necessary, the LAR, regarding the 
capacity assessment and opportunities for objection and 
review. Researchers should provide notice to the potential 
participant and/or LAR that an assessment will be con-
ducted and the consequences (if any) of a determination 
of incapacity.
As part of a research protocol, the Task Force recom-
mends that potential participants and/or LARs should 
be notifi ed of a planned capacity assessment, as well as 
the results of the assessment and any consequences of a 
determination of incapacity. Providing notice promotes 
transparency by alleviating any concerns that an individ-
ual might be involved in research without the knowledge 
of the participant or LAR. It also demonstrates respect for 
the prospective participant by presenting an opportunity 
for the individual or his/her LAR to object to either the 
capacity assessment or the results of the evaluation. When 
capacity assessments are contested, the most ethical 
methods to be used for the initial capacity assessment, 
as well as how capacity will be monitored through the 
course of the study (if appropriate), and include informa-
tion about who will conduct the assessment and his/her 
qualifi cations.
D. Legally Authorized Representatives 
When researchers are unable to obtain fi rst-person 
informed consent from a potential participant, research-
ers may—depending on the nature of the study and the 
risk-benefi t ratio—be permitted to enroll an individual 
using surrogate informed consent or according to a 
potential participant’s RAD. However, neither the federal 
nor state governments have directly addressed who 
should act as a research legally authorized representative 
(LAR) for the cognitively impaired.25 If the legislature or 
Department of Health promulgates rules in the future 
regarding who may consent, different considerations and 
standards of decision-making should apply to research 
than to treatment.26 
The Task Force recognizes that, ideally, an individual 
should select an LAR before s/he no longer has consent 
capacity, using a legally binding document, such as a 
health care proxy or RAD. The Task Force prefers such 
appointments because it assumes that the appointed 
LAR has a close relationship with the individual and that 
a discussion regarding research preferences has taken 
place. In some cases, a cognitively impaired adult may 
retain suffi cient capacity to choose a research proxy—a 
research agent—to make research decisions on his/her 
behalf, but lack capacity to consent to research participa-
tion him/herself.27 Strict procedural mechanisms and 
safeguards, similar to those used in a health care proxy 
designation appointed while the individual has consent 
capacity, should be in place to ensure that an individual’s 
appointment of a research agent using a legally bind-
ing document is an unbiased and free choice.28 The Task 
Force also recommends the placement of restrictions on 
who may serve as an LAR to ensure that participants are 
adequately protected.29
Where an RAD has not been previously executed, it 
may be permissible, in some cases, for individuals lack-
ing consent capacity to be enrolled in a research protocol 
with the consent of an LAR. Federal law clearly contem-
plates allowing surrogates to consent to research involv-
ing adults who lack consent capacity.30 An LAR is defi ned 
under the Common Rule as “an individual or judicial 
body authorized under applicable law to consent on be-
half of a prospective subject to the subject’s participation 
in the procedure(s) involved in the research….”31 How-
ever, federal law defers to the states to establish who may 
serve as an LAR, looking to their formulations of LAR 
to determine who may consent to research conducted in 
that state. Because New York’s laws for human subjects 
research do not provide a research-related LAR hierarchy, 
the 2010 passage of the Family Health Care Decisions 
Act (FHCDA) changed the legal landscape by permitting 
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benefi ts and decide if enrollment in a research protocol 
would be appropriate.38 
The Task Force recommends that the role and re-
sponsibilities of an ICM may vary, from monitoring the 
informed consent process to advocating on behalf of po-
tential and current research participants, and the degree 
of involvement of the ICM would be determined by an 
IRB. After reviewing the research protocol and the risk-
benefi t level involved, an IRB may determine the scope of 
responsibilities of an ICM. 
2. Medically Responsible Clinicians (MRCs)
Depending on the research study and risk level 
involved, use of an MRC for each participant may be a 
necessary safeguard to protect cognitively impaired indi-
viduals. An MRC is a licensed medical doctor skilled and 
experienced in working with the research population and 
is independent from the study. Ideally, this person should 
be the physician already attending to the participant’s 
health care needs—who is not involved in the research—
but an MRC may also be any qualifi ed physician not 
affi liated with the research study. While the primary role 
of an MRC is to serve as an advisor to an individual or 
LAR regarding research participation, additional duties 
include: (1) confi rming that a participant provided assent 
to be enrolled in the research; (2) observing the individual 
for possible dissent to continued participation; and (3) 
monitoring the individual for any signs of harm as a 
result of research participation.39 Thus, use of an MRC is 
an important safeguard for high risk studies because the 
physician acts as an advocate for cognitively impaired 
individuals. The MRC serves as a mechanism to assure 
that the physical and emotional well-being of participants 
are looked after by an outside third party.
3. Multiple Project Assurances (MPAs)
According to New York law, the consent of the 
Commissioner of Health is required for all non-federally 
regulated research involving “incompetent persons [and] 
mentally disabled persons,” regardless of the risk catego-
ry.40 However, to streamline the review process, the Task 
Force recommends that the Department of Health should 
develop MPAs41 to ensure a timely and thorough review 
of research protocols by IRBs. An MPA is an assurance 
between the Department of Health and a research entity 
or institution that pledges that all members of the entity 
or institution will comply with human subjects research 
policies issued by the state.
The Task Force recommends the use of a state MPA 
to obviate the need for full case-by-case Commissioner/
Department of Health review for research involving cog-
nitively impaired individuals that involves minimal risk 
or a minor increase over minimal risk, with or without a 
prospect of direct benefi t, and for research that involves 
more than a minor increase over minimal risk with a 
prospect of direct benefi t. However, for research that 
involves more than a minor increase over minimal risk, 
alternative may be to decline to enroll the individual in 
the research protocol. However, in some cases, alterna-
tives short of non-enrollment could appropriately deal 
with any objection, such as a second capacity assessment. 
Readily available review procedures allow individuals an 
opportunity to request further information or a second 
opinion where they or their LARs see fi t. Furthermore, 
steps should be taken during the notifi cation process to 
ensure that the results of the capacity assessment re-
main confi dential and that the privacy of the individual 
is respected. Finally, the Task Force recommends that 
researchers inform patients of whether the results of the 
assessment will be entered into an individual’s medical 
record.
F. Additional Safeguards for Research Participants 
Lacking Consent Capacity
Additional protections might sometimes be neces-
sary to safeguard the rights of participants who lack 
consent capacity, particularly when a study involves a 
minor increase over minimal risk or more than a minor 
increase over minimal risk, and when there is no pros-
pect of direct benefi t to the participant. The amount and 
scope of additional safeguards that the Task Force recom-
mends for research with this population depends on the 
level of risk and the likelihood of direct benefi t that the 
research protocol offers to the research participant. Such 
protective measures may include, but are not limited to: 
(1) independent consent monitors; (2) medically respon-
sible clinicians; (3) state multiple project assurances; and 
(4) additional reporting requirements.
1. Independent Consent Monitors (ICMs)
By commonly accepted defi nitions, an ICM is an 
individual not affi liated with the study or research 
institution, who is designated by an IRB to monitor the 
informed consent process34—for example, when LAR 
consent is required. In some cases, this safeguard may 
provide additional protection for potential participants, 
because an ICM’s duties include ensuring that as a wit-
ness to the consent process, verifi cation of valid consent 
is properly obtained.35 An ICM provides confi rmation 
that adults lacking consent capacity are enrolled in 
research protocols only when appropriate informed con-
sent procedures are followed. In addition, an ICM may 
also confi rm that LARs understand the goals and risks of 
the research by observing the informed consent process.36 
Furthermore, an ICM may provide independent as-
surance that an adult lacking consent capacity is enrolled 
in research only when there is suffi cient evidence that 
such participation is consistent with the person’s prefer-
ences and/or interests. For some research protocols, an 
ICM may have a more active role as an advocate for the 
potential participant and LAR during the recruitment 
process and possibly for the entire research study.37 The 
ICM may serve as a resource to help potential par-
ticipants and LARs understand the potential risks and 
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The disclosure of adverse events45 and unanticipated 
problems46 that result from research participation pro-
motes transparency and may further protect the welfare 
of research participants.47 The Offi ce of Human Research 
Protections (OHRP) has suggested defi nitions of “adverse 
events”—which are not (in all cases) necessarily report-
able to the IRB or federal agency—and “unanticipated 
problems” which must be reported; the defi nitions over-
lap but an occurrence might be either an adverse event or 
an unanticipated problem without being the other. While 
most adverse events are not unanticipated problems, and 
only some unanticipated problems are adverse events, 
only a small proportion of adverse events are unantici-
pated problems. 
Because the severity of any given adverse event 
may range from minimal to serious, because the natural 
progression of an illness or condition under study will 
vary, and because the severity and frequency of antici-
pated problems inherent to the research will vary, IRBs 
should determine, based on the research protocol, which 
events would require immediate action by the researcher 
or institution. Any reasonable possibility that a protocol 
may have caused serious or life-threatening harm or 
death requires immediate reporting and attention by the 
researcher and IRB to provide any corrective or preventa-
tive action.
The Task Force recommends that for both IRBs and 
researchers, any non-federal research protocol should 
contain methods for the identifi cation, management, and 
reporting of adverse events and unanticipated problems 
that may occur during the course of a research protocol, 
comparable to those contemplated by the federal Com-
mon Rule.48 
Conclusions
The Task Force’s Report and Recommendations for Re-
search with Human Subjects Who Lack Consent Capacity are 
the result of a multi-year effort to respond to appeals for 
guidance from New York State IRBs, investigators, and 
research institutions on how to conduct ethical research 
involving adults who lack consent capacity. Although 
New York State law governs human subjects research for 
a subset of research conducted in the state by providing 
mechanisms for ensuring voluntary informed consent for 
participants and IRB review of research protocols, it does 
not provide any special oversight mechanisms for re-
search involving this particular population. Despite calls 
to do so, federal law also does not provide safeguards 
or special protections for research involving “mentally 
disabled persons.”49 The absence of such guidelines or 
regulations may lead to unethical or unsafe research pro-
tocols or the dearth of important research into the broad 
range of diseases that impair cognition.
Thus, an underlying goal of the Task Force’s work 
is to ensure that research protocols are available to all 
without a prospect of direct benefi t, a state MPA should 
not be a valid release from review by the Department 
of Health. In these cases, if an IRB concludes that the 
research is of vital importance to either current research 
participants and/or those similarly situated, that the risks 
are reasonable in relation to such vital importance, and 
appropriate safeguards are in place, the Department of 
Health may: (1) reject the study and the research could 
not be approved by the IRB, (2) approve the study and 
the research could be approved by the IRB, or (3) convene 
a special review panel of experts which will review the 
study and issue recommendations to the IRB on whether 
the study should be approved, and the IRB will make the 
fi nal decision to approve or reject the protocol.
4. Reporting Requirements
While most research conducted in the state is feder-
ally regulated or overseen, there is a small portion of 
research that is not under federal purview. The Task Force 
recommends that research involving individuals unable 
to provide consent under Public Health Law 24-A should 
be subject to federal reporting requirements.42 These 
reporting requirements will promote accountability and 
transparency and may include, if appropriate, evalua-
tions of capacity of participants, including the method(s) 
used to assess capacity; procedures used to identify 
LARs for surrogate consent to research; and a summary 
of various risk levels involved in approved protocols. 
Furthermore, the Task Force recommends that IRBs be 
required to report to the Department any violations of ap-
proved principles and policies which the institution has 
promulgated.43 
The Task Force recommends that researchers con-
ducting studies under New York State’s law governing 
HSR that involve individuals unable to provide con-
sent should be subject to federally mandated reporting 
requirements and provide such documentation to the 
IRB. Under federal regulations, researchers are required 
to submit extensive documentation to an IRB as part of 
the review and approval process.44 In addition, the Task 
Force recommends that researchers should disclose rel-
evant information to potential participants and LARs of 
how the study will be ethically conducted to ensure that 
the rights and welfare of participants are protected. 
Once the study is under way, the Task Force recom-
mends that researchers should provide regular updates 
on the status of the participant and the general progress 
of the study to the participant and/or LAR. They should 
report any substantial concerns regarding an individual’s 
participation to the LAR in ordinary language so that     
s/he remains fully informed. In addition, the researcher 
should remind participants and LARs of the availabil-
ity of the researcher throughout the study to address 
any questions. Only with full disclosure to participants, 
LARs, and IRBs of the status and progress of the research 
can all parties be confi dent that the study is being con-
ducted in an ethical and safe manner.
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7. For more information, particularly regarding the justifi cations for 
the Task Force’s recommendations and the legal implications of 
research involving adults lacking consent capacity, see the Task 
Force’s full report, Report and Recommendations for Research with 
Human Subjects Who Lack Consent Capacity.
8. Possible justifi cations may include that these institutionalized 
settings provide additional oversight and monitoring of 
participants and the research and that these settings contribute to 
the overall standardization and integrity of the data. 
9. Many of these residents have an additional layer of vulnerability 
due to their heavy reliance for care on staff members, some 
of whom may be part of the research study or involved in 
recruitment, and may therefore be subject to real or perceived 
coercion by staff to participate. 
10. The Nat’l Comm’n for the Protection of Human Subjects 
of Biomedical and Behavioral Research, “Report and 
Recommendations: Research Involving Children,” 1977, http://
bioethics.georgetown.edu/pcbe/reports/past_commissions/
Research_involving_children.pdf. 
11. 45 C.F.R. §§ 46.103, 46.109, 46.116-17, 46.405.
12. 45 C.F.R. § 46 (Subpart D); “1998 New York State Work Group 
Report,” supra note 3, at 14; Offi ce of the Maryland Attorney 
General, “Final Report of the Maryland Attorney General’s 
Research Working Group,” 1998, at A-17 [hereinafter “Maryland 
Attorney General Report”].
13. Offi ce for Human Research Protections, “Secretary’s Advisory 
Committee on Human Research Protections (SACHRP), Appendix 
B,” http://www.hhs.gov/ohrp/sachrp/sachrpltrtohhssecapdb.
html, accessed April 16, 2013.
14. In the context of the report, analogous research includes any 
previously performed studies with similar characteristics (i.e., 
research population or cognitive impairment examined) from 
which fi ndings can be applied to the current study.
15. It may be prudent to separate therapeutic intent from therapeutic 
benefi t, especially when the extent of potential benefi t has not 
been established. See J.J. Fins, “A Proposed Ethical Framework 
for Interventional Cognitive Neuroscience: A Consideration of 
Deep Brain Stimulation in Impaired Consciousness,” Neurological 
Research 22, no. 3 (2000): 273-78, at 274-275. It may be helpful for 
IRBs to use such considerations when attempting to establish the 
permissibility of studies with more than a minor increase over 
minimal risk in the absence of clear data regarding the study’s 
potential benefi t.
16. Federal regulations regarding human subjects research with 
children permit this type of research protocol if, among other 
requirements, the IRB determines that the research is “likely to 
yield generalizable knowledge about the subjects’ disorder or 
condition which is of vital importance for the understanding or 
amelioration of the subjects’ disorder or condition.” 45 C.F.R. § 
46.406(c).
17. See Fins, “A Proposed Ethical Framework for Interventional 
Cognitive Neuroscience,” 274-275. 
18. One model for such a review panel is the federal 407 Review 
Children’s Panels under the Common Rule, which examines 
research protocols involving children that are otherwise not 
approvable because of their risk level. See 45 C.F.R. § 46.407.
19. These experts would not be restricted to those residing in 
New York State. Instead, panelists would be selected for their 
knowledge and expertise in the particular area being studied. 
20. Some may argue that for individuals not capable of providing 
informed consent, there is no need to ask them for assent, and 
that instead use of surrogate consent is suffi cient. However, this 
view ignores the fact that capacity is not an absolute; requiring 
assent from these participants allows them to retain a measure 
of control over their ability to make decisions. In addition, in the 
past, there has been no requirement that impaired participants 
individuals, including individuals who lack consent 
capacity, so that they may also experience the benefi ts, 
risks, and burdens of research as their non-cognitively 
impaired peers, while also ensuring the appropriate level 
of protections. Although the guidelines focus only on the 
inclusion of these individuals in research in New York 
State, the recommendations could serve as a model for 
the development of other policies in other states and at 
the federal level.
For more information regarding the Task Force’s 
analysis and recommendations, as well as more on the le-
gal implications of research involving adults lacking con-
sent capacity, see the Task Force’s full report, Report and 
Recommendations for Research with Human Subjects Who 
Lack Consent Capacity, at: http://www.health.ny.gov/
regulations/task_force/reports_publications/.
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for adverse event reporting. 45 C.F.R. § 46.103(a) & (b)(5). The 
IRB assurance must include: “Written procedures for ensuring 
prompt reporting to the IRB, appropriate institutional offi cials, 
and the department or agency head of (i) any unanticipated 
problems involving risks to subjects or others or any serious or 
continuing noncompliance with this policy or the requirements or 
determinations of the IRB; and (ii) any suspension or termination 
of IRB approval.” 45 C.F.R. § 46.103(b)(5). See also OHRP, 
“Guidance on Reviewing and Reporting Unanticipated Problems 
Involving Risks to Subjects or Others and Adverse Events,” (2007) 
http://www.hhs.gov/ohrp/policy/adverntguid.html. N.Y. Pub. 
Health Law Art. 24-A does not require such reporting. 
49. 45 C.F.R. § 46.111.
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National Institutes of Health/National Institute of Mental 
Health employ a Clinical Research Advocate, which is a hybrid 
of a traditional ICM and of an advocate for vulnerable research 
participants. These Clinical Research Advocates provide 
assistance to potential and current research participants by 
overseeing the informed consent process and also assess the 
surrogate decision-makers who may be involved in the process 
of informed consent. Mary Ellen Cadman, Presentation, Human 
Subjects Protection Unit, at PRIM&R 2008 (Nov. 18, 2008). 
38. The ICM should be familiar with the clinical aspects of the 
research protocol, understand and be able to answer questions, 
especially those concerning risk-benefi t information, in plain 
language. This person could also address additional concerns 
from participants and LARs during the course of the research 
study and may help a participant and his/her LAR decide 
whether continued participation is appropriate. For potential 
participants without consent capacity, an ICM should offer 
insight to the LAR as to whether or not the individual should be 
enrolled in a particular study while respecting the diffi culty an 
LAR may face when making diffi cult decisions concerning the 
loved one. Ideally, an ICM would have experience serving as 
a surrogate decision-maker for a person who has had a similar 
disorder affecting consent capacity. J.F. & F.G. Miller, “Enrolling 
Decisionally Incapacitated Subjects in Neuropsychiatric 
Research,” CNS Spectrums 5, no. 10 (2000): 32-40 (proposing a 
matrix of individuals and perspectives, which would assist with 
enrollment decisions). 
39. “1998 New York State Work Group Report,” supra note 3, at 21.
40. N.Y. Pub. Health Law § 2444.
41. A State MPA would be like a Federalwide Assurance (FWA), 
a document fi led with OHRP by an institution, which ensures 
that all of its human subject research activities, regardless of the 
funding source, will comply with the federal research protections 
provided in the Common Rule.
42. Many states require additional oversight and reporting standards 
beyond the federal standards. At this time, the Task Force 
recommends that the federal standards serve as minimum 
standards for research that falls under N.Y. Pub. Health Law Art. 
24-A. 
43. N.Y. Pub. Health Law § 2444(2).
44. See generally 45 C.F.R. §§ 46.109, 46.111, 46.116-17. Common 
documentation requirements include: (1) evidence of appropriate 
education training in human subjects research protection; 
(2) assessment of potential participants’ capacity, including 
information on who conducted the assessments and how 
decision-making capacity was assessed; (3) procedures for 
re-evaluating a participant’s capacity; (4) privacy protections 
to protect potential participants’ information; (5) procedures 
by which the health and safety of participants were monitored 
during the course of the research, including appropriate 
consultation with the participant’s LAR or MRC, if appropriate; 
(6) unanticipated adverse events involving risk to participants or 
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